4-Cyano-1H-imidazole Derivatives for Selective c-FMS Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective and selective protein tyrosine kinase inhibitors, particularly for c-fms kinase, which are crucial in addressing various diseases including cancer and inflammatory conditions.
Innovation Solution
Development of novel compounds such as 4-Cyano-1H-imidazole-2-carboxylic acid derivatives, including their solvates, hydrates, and pharmaceutically acceptable salts, which act as potent inhibitors of c-fms kinase, for use in pharmaceutical compositions to treat a range of diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current protein tyrosine kinase inhibitors are used, then some kinase activity is inhibited, but selectivity for c-fms kinase is insufficient
Solution Approach 1:
The patent applies local quality by designing a inhibitor molecule with specific functional groups positioned to interact with unique residues in the c-fms kinase binding pocket. The compound features a heteroaryl ring system with specific substituents that form selective hydrogen bonds and hydrophobic interactions with c-fms, distinguishing it from other kinase inhibitors that lack this localized specificity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as heteroaryl ring type, substituent position, and side chain length to optimize selectivity. The structure-activity relationship studies demonstrate how changing these parameters enhances binding affinity for c-fms while reducing off-target effects on other kinases.
2Productivity
If non-selective protein tyrosine kinase inhibitors are used, then multiple kinases are inhibited, but therapeutic efficacy for c-fms-driven diseases is reduced
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibitor landscape into specific subcategories based on selectivity profiles. The c-fms selective inhibitor represents a distinct segment from broad-spectrum kinase inhibitors, allowing for targeted therapeutic intervention without the complexity of managing multiple kinase inhibition effects.
3Reliability
If existing kinase inhibitor structures are used, then general kinase inhibition is achieved, but potency against c-fms is insufficient
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the core heteroaryl structure and key substituents based on computational modeling and preliminary binding assays. This preliminary design phase identifies the most promising structural motifs before full synthesis and testing, reducing the need for extensive structural modifications later while achieving high potency.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.